

ORIGINAL ARTICLE

# Epidemiological time series studies of PM<sub>2.5</sub> and daily mortality and hospital admissions: a systematic review and meta-analysis

R W Atkinson, <sup>1</sup> S Kang, <sup>1</sup> H R Anderson, <sup>1,2</sup> I C Mills, <sup>3</sup> H A Walton<sup>2,4</sup>

► Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ thoraxinl-2013-204492).

<sup>1</sup>Population Health Research Institute and MRC-PHE Centre for Environment and Health, St George's. University of London, London, UK <sup>2</sup>MRC-PHE Centre for Environment and Health. King's College London, London, UK <sup>3</sup>Public Health England, Centre for Radiation, Chemical and Environmental Hazards, Chilton, Oxfordshire, UK <sup>4</sup>NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK

# Correspondence to

Dr R W Atkinson, Population Health Research Institute and MRC-PHE Centre for Environment and Health, St George's, University of London, Cranmer Terrace, London SW17 ORE, UK; atkinson@sgul.ac.uk

Received 11 September 2013 Revised 28 February 2014 Accepted 6 March 2014 Published Online First 4 April 2014





**To cite:** Atkinson RW, Kang S, Anderson HR, *et al. Thorax* 2014;**69**:660–665.

#### **ABSTRACT**

**Background** Short-term exposure to outdoor fine particulate matter (particles with a median aerodynamic diameter <2.5  $\mu$ m (PM<sub>2.5</sub>)) air pollution has been associated with adverse health effects. Existing literature reviews have been limited in size and scope.

**Methods** We conducted a comprehensive, systematic review and meta-analysis of 110 peer-reviewed time series studies indexed in medical databases to May 2011 to assess the evidence for associations between  $PM_{2\cdot5}$  and daily mortality and hospital admissions for a range of diseases and ages. We stratified our analyses by geographical region to determine the consistency of the evidence worldwide and investigated small study bias. **Results** Based upon 23 estimates for all-cause mortality, a 10  $\mu$ g/m³ increment in  $PM_{2\cdot5}$  was associated with a 1.04% (95% CI 0.52% to 1.56%) increase in the risk of death. Worldwide, there was

associated with a 1.04% (95% CI 0.52% to 1.56%) increase in the risk of death. Worldwide, there was substantial regional variation (0.25% to 2.08%). Associations for respiratory causes of death were larger than for cardiovascular causes, 1.51% (1.01% to 2.01%) vs 0.84% (0.41% to 1.28%). Positive associations with mortality for most other causes of death and for cardiovascular and respiratory hospital admissions were also observed. We found evidence for small study bias in single-city mortality studies and in multicity studies of cardiovascular disease.

**Conclusions** The consistency of the evidence for adverse health effects of short-term exposure to PM<sub>2·5</sub> across a range of important health outcomes and diseases supports policy measures to control PM<sub>2·5</sub> concentrations. However, reasons for heterogeneity in effect estimates in different regions of the world require further investigation. Small study bias should also be considered in assessing and quantifying health risks from PM<sub>2·5</sub>.

# INTRODUCTION

The adverse health effects of exposure to outdoor particulate matter air pollution are of concern to governments and health organisations worldwide. The evidence for these health effects has come from studies of the clinical, mechanistic and epidemiological evidence of short-term and long-term exposures. While the epidemiological evidence relating short-term exposure to PM<sub>10</sub> (particles with a median aerodynamic diameter <10 µm) and related metrics (black smoke, total suspended particles) with health effects is substantial, there are relatively few studies of fine particles measured as PM<sub>2.5</sub> (particles with a median aerodynamic

# Key messages

## What is the key question?

► Is there convincing and consistent evidence worldwide that short-term exposure to outdoor fine particulate matter (particles with a median aerodynamic diameter <2.5 μm (PM<sub>2.5</sub>)) air pollution is associated with increased risk of death and emergency admission to hospital?

#### What is the bottom line?

▶ We found evidence for adverse health effects of short-term exposure to PM<sub>2.5</sub> across a range of important health outcomes, diseases and age groups with substantial variation between different regions of the world that needs explanation.

#### Why read on?

▶ Our study provides a systematic, quantitative summary of the time series literature and reports new findings that suggest larger associations for respiratory causes of death than for cardiovascular causes and that the presence of publication bias in the literature could have important implications for public health policy.

diameter <2.5  $\mu$ m). Reviews of the evidence linking exposure to PM<sub>2.5</sub> to adverse health effects have relied upon a small number of published studies, restricted in health outcomes and geographical coverage, or focused on differential PM<sub>2.5</sub> toxicity.<sup>3–11</sup>

To summarise the existing evidence we conducted a comprehensive and systematic meta-analysis of time series studies of daily PM<sub>2.5</sub> and daily mortality and hospital admissions published worldwide in the peer reviewed literature to May 2011. This included all disease outcomes for which there were sufficient studies for meta-analysis and combined results from single-city and multicity studies. We focused our analysis on single-pollutant rather than multipollutant models and upon all-year results in order to maximise the number of estimates available for inclusion in the review. We present estimates for WHO regions and assess between-region heterogeneity. We also investigate whether there is evidence of publication (small study) bias between single-city study estimates and between multicity summary estimates.

#### **METHODS**

#### Systematic ascertainment of relevant studies

Time series (including case crossover) studies published in peer reviewed journals and indexed in online databases to May 2011 (no start date specified) were identified via search strings using terms relating to study design, pollutant and health outcomes. A sifting process identified (from study titles, abstracts and the full paper) those time series studies suitable for inclusion in the review. Study eligibility depended upon the details of the study design, statistical methods used and presentation of regression estimates and other data in numerical format. Further details are given in the online supplementary material.

#### Extraction and coding of data

Study details were entered into a Microsoft Access database (Microsoft Office 2010, Microsoft Corporation) and included citation information (title, authors, date of publication, etc) and details of effect estimates including health outcome (mortality or admission), diagnosis (International Classification of Diseases codes), age, and so on, and details of the pollutants (unit of measurement, range of exposure, etc). These data were used to calculate standardised effect estimates expressed as the percentage change (and 95% CI) in the mean number of daily events associated with a 10 µg/m<sup>3</sup> increase in PM<sub>2.5</sub> concentration. The short-term relationships between air pollution and health effects are determined for given time lags (in days) between exposure and health events and investigators vary in which lags they study and report.<sup>12</sup> Hence an a priori lag selection protocol was devised and used to choose lag estimates for inclusion in the review without introducing bias (see online supplementary material for details). Additional data entry included the coding of the WHO region in which the study occurred (see online supplementary material, table S1). Studies were reviewed by a single statistician/epidemiologist before coding. All papers were read by RWA and data range checked prior to meta-analysis.

#### Meta-analysis

In the time series literature many cities have been studied on more than one occasion, in single-city studies and as part of a larger, coordinated multicity investigation. To ensure results from a city only appeared once in any one meta-analysis we applied an a priori estimate-selection protocol (see online supplementary material for details).

We conducted meta-analyses only if there were 4+ single city estimates or if the set of estimates contained a multicity study summary estimate. Within each WHO region we conducted a two stage meta-analysis using a random-effects model for each stage. 13 In the first stage, single-city estimates were pooled to provide a summary estimate of the evidence from single-city studies. In the second stage, these summary estimates were pooled with the selected multicity study estimates to obtain a WHO region-specific summary estimate of the evidence. To assess heterogeneity between WHO regions we used the  $I^2$  statistic which indicates the proportion of total variability between effect estimates due to heterogeneity.  $I^4$   $I^2$  statistics in the range 0 to 30, 30 to 50 and >50 generally indicate low, moderate and high heterogeneity, respectively. Finally, a global summary estimate was calculated from WHO region-specific single-city summary estimates and multicity study estimates.

## Assessment of small study bias

We investigated our selected single-city estimates and our pooled single-city and selected multicity estimates for evidence of small study bias using the methods of Begg and Egger.<sup>15</sup> <sup>16</sup> The former uses an adjusted rank correlation method to examine the association between study estimates and their variance whereas the latter uses a regression approach. The impact of adjustment for small study bias was assessed using the 'trim and fill' method.<sup>17</sup> This method removes studies until symmetry in the funnel plot is achieved, recalculating the centre of the funnel before the removed studies are replaced together with their 'missing' mirror-image counterparts. A revised summary estimate is then calculated using all of the original studies, together with the hypothetical 'filled' studies. Our overall assessment of the evidence for small study bias was based upon the combined evidence presented by all three techniques.

All analyses were conducted in STATA (STATA/SE V.10, StataCorp Texas).

#### **RESULTS**

One hundred and ten time series studies of daily mortality (68) and hospital admissions (54) indexed in medical databases to May 2011, and providing numerical effect estimates, reported results for PM<sub>2.5</sub> (see online supplementary material, table S2). Table 1 details the number of studies tabulated by outcome, disease, WHO region, age group and multicity versus single-city study design. The majority of studies of PM<sub>2.5</sub> and daily mortality and hospital admissions have been conducted in North America and Europe with a small number of studies in other regions of the world. The most frequently reported estimates for daily mortality were for the all-ages group, followed by the 65 + years group. For most populations the latter comprised a large proportion of the all-ages group so we confined our mortality analyses to the all-ages group. For hospital admissions we focused upon age-specific estimates in children and the elderly (ages 0–14 years and 65+ years, respectively). While the majority of studies were conducted in single cities, a substantial number reported findings from multicity studies.

# Mortality

Summary estimates (95% CIs) per 10  $\mu$ g/m³ increment in PM<sub>2.5</sub> and all-age, all-cause and cause-specific mortality are presented in figure 1. All associations were positive and for all, except chronic COPD, lower CIs were above unity. For all-cause mortality, 23 single-city and multicity study estimates were selected for meta-analysis from the 43 estimates identified in the review (see online supplementary material, figure S1). The overall random effects summary estimate was 1.04% (95% CI 0.52% to 1.56%) per 10  $\mu$ g/m³ increment in PM<sub>2.5</sub>. WHO region-specific summary estimates varied substantially ( $I^2$ =93%) from 0.25% to 2.08% (table 2).

While fewer estimates were available for cardiovascular (see online supplementary material, figure S2) and respiratory (see online supplementary material, figure S3) mortality, the overall summary estimate for all respiratory causes of death was larger than for all cardiovascular causes, 1.51% (95% CI 1.01% to 2.01%) versus 0.84% (95% CI 0.41% to 1.28%), respectively. For both causes of death, associations were positive in all WHO regions (table 2) and heterogeneous for cardiovascular deaths ( $I^2=76\%$ ) but not respiratory deaths ( $I^2=0\%$ ). Associations between PM<sub>2.5</sub> and death from ischaemic heart disease, stroke and COPD were 3.36% (0.68%, 6.10%), 1.85% (0.74%, 2.97%) and 2.86% (-0.12%, 5.93%) per 10 µg/m³, respectively, although the evidence was restricted to a small number of single-city and multicity studies (see online supplementary material, table S3 and figures S4–S6).


Multicity study Outcome		Total		Multicity study		Single-city study	
		Mortality	Hospital admission	Mortality	Hospital admission	Mortality	Hospital admission
Total		68	54	17	11	51	43
Disease	Respiratory	33	43	7	9	26	34
	Cardiovascular	41	34	9	9	32	25
	All-cause	56	2	15	0	41	2
	Other	7	3	2	2	5	1
WHO region	American region A	33	31	13	8	20	23
	European region A	20	10	2	1	18	9
	Western Pacific region B	6	6	0	0	6	6
	American region B	6	2	0	0	6	2
	Western Pacific region A	4	4	3	2	1	2
	South-East Asia region D	0	1	0	0	0	1
Age group	All ages	54	21	16	1	40	20
3 3 1	Elderly	26	28	5	9	21	19
	Not elderly	4	4	1	1	3	3
	Adult	1	2	0	0	1	2
	Young adult	0	9	0	2	0	7
	Children	1	18	0	3	1	15
	Other	2	3	0	0	2	3

#### **Hospital admissions**

Table 3 gives summary estimates for all-age, cardiovascular and respiratory causes of hospital admissions with individual study results presented in online supplementary material, figures S7 and S14.

PM<sub>2.5</sub> concentrations were positively associated with increases in risk of admission for cardiovascular diseases, 0.90% (95% CI 0.26% to 1.53%) and respiratory diseases, 0.96% (95% CI

-0.63% to 2.58%) per 10 μg/m³, respectively, with heterogeneity between WHO regions for respiratory diseases (I²=80%) but not cardiovascular diseases (I²=0%). Figure 2 illustrates summary estimates for specific cardiovascular diseases in ages 65+ years and for respiratory diseases in ages 65+ years and children aged 0–14 years. All associations were positive except for stroke and for all, except COPD including asthma, lower CIs exceeded 0%. Details of WHO-specific summary estimates are



**Figure 1** Summary estimates (95% confidence intervals) for all-cause and cause-specific mortality.

 Table 2
 Meta-analysis results for all-age, all-cause mortality and cause-specific mortality by WHO region

	All*	Selected†		l <sup>2</sup>
WHO region	(SC/MC)	(SC/MC)	RE (95% CI)‡	(%)§
All Cause				
AMR A	13/12	5/2	0.94 (0.73 to 1.16)	93
AMR B	4/0	2/0	2.08 (1.60 to 2.56)	
EUR A	12/1	9/1	1.23 (0.45 to 2.01)	
WPR A	0/1	0/1	0.90 (-0.70 to 2.53)	
WPR B	5/0	3/0	0.25 (0.06 to 0.44)	
Summary¶	-	4/4	1.04 (0.52 to 1.56)	
Cardiovascular				
AMR A	10/3	6/1	0.84 (0.47 to 1.20)	76
AMR B	3/0	2/0	0.13 (-0.71 to 0.98)	
EUR A	6/1	6/1	2.26 (1.23 to 3.29)	
WPR B	4/0	2/0	0.56 (0.31 to 0.81)	
Summary¶	-	4/2	0.84 (0.41 to 1.28)	
Respiratory				
AMR A	4/5	4/1	1.39 (0.62 to 2.16)	0
AMR B	3/0	2/0	0.88 (-1.88 to 3.71)	
EUR A	7/0	7/0	3.81 (0.57 to 7.16)	
WPR B	4/0	2/0	1.49 (0.04 to 2.96)	
Summary¶	-	4/1	1.51 (1.01 to 2.01)	

<sup>\*</sup>Numbers of single-city(SC)/multicity (MC) estimates available from all studies.
†Numbers of single-city(SC)/multicity (MC) estimates selected for meta-analysis (see estimate selection protocol in Methods section).

<sup>‡</sup>Random effects summary estimate (95% CI) per 10 μg/m<sup>3</sup>.

<sup>§</sup>I<sup>2</sup> statistic for heterogeneity.

<sup>¶</sup>Estimate numbers for 'Summary' refers to the number of pooled (from single-city estimates) and multicity estimates used to calculate the overall summary estimate across WHO regions.

AMR, Region of the Americas; EUR, European Region; WPR/SEAR, South East Asian Region.

**Table 3** Meta-analysis results for all-age, cardiovascular and respiratory hospital admissions by WHO region

	•	•	•	
WHO region	All* (SC/MC)	Selected† (SC/MC	RE (95% CI)‡	l <sup>2</sup> (%)§
Cardiovascular				
AMR A	2/0	1/0	0.00 (-2.85 to 2.93)	0
EUR A	4/1	4/1	0.91 (0.17 to 1.66)	
WPR A	1/0	1/0	1.04 (-0.30 to 2.39)	
Summary¶	-	3/1	0.90 (0.26 to 1.53)	
Respiratory				
AMR A	1/0	1/0	-2.00 (-6.00 to 2.17)	80
EUR A	3/0	3/0	1.90 (-0.18 to 4.02)	
SEAR D	1/0	1/0	0.12 (0.08 to 0.16)	
WPR A	1/0	1/0	2.38 (1.04 to 3.73)	
Summary¶	-	4/0	0.96 (-0.63 to 2.58)	

\*Numbers of single-city(SC)/multicity (MC) estimates available from all studies. †Numbers of single-city(SC)/multicity (MC) estimates selected for meta-analysis (see estimate selection protocol in Methods section).

‡Random effects summary estimate (95% CI) per 10 μg/m<sup>3</sup>.

§I<sup>2</sup> statistic for heterogeneity.

¶Estimate numbers for 'Summary' refers to the number of pooled (from single-city estimates) and multicity estimates used to calculate the overall summary estimate across WHO regions.

given in online supplementary material, tables S4 and S5, and study-specific estimates in online supplementary material, figures S7–S13 and S15–S20.

# Small study bias

The impact of adjustments for small study bias in single-city studies within WHO regions and between the pooled single-city and multicity estimates for all-age, all-cause and cause-specific mortality are shown in table 4. We found evidence for small study bias in single-city mortality studies and in multicity studies of cardiovascular disease.

Figure 3 illustrates, for cardiovascular mortality, this adjustment using a funnel plot of individual study estimates and showing the random effects summary estimates with, and without, inclusion of the two 'filled' estimates identified by the 'trim and fill' procedure. We did not find evidence of small study bias in either single-city or multicity estimates for cardiovascular or respiratory hospital admissions (data not shown).

#### DISCUSSION

In this systematic review we identified 110 ecological time series studies of short-term exposure to outdoor PM<sub>2.5</sub> and daily mortality and hospital admissions indexed in medical databases up to May 2011. Our meta-analysis of effect estimates from these studies indicated positive associations with daily all-cause and cause-specific mortality and cause-specific and age-specific hospital admissions, with some evidence of heterogeneity. We also found evidence for small study bias in single-city estimates and between pooled and multicity estimates.

There are a number of plausible biomedical explanations for associations between short-term exposure to fine particles and adverse health outcomes. <sup>5</sup> <sup>6</sup> It is hypothesised that small effects cause clinical events when experienced by individuals who are already vulnerable due to existing chronic or acute disease. Our review indicates that such effects are observed even at the relatively low levels of fine particles found in developed countries. Our results reinforce the public health importance of fine particles on health. While the estimates are small, the impact is substantial because the entire population is exposed. Impact




Figure 2 Summary estimates (95% confidence intervals) for cardiovascular and respiratory hospital admissions.

assessments of PM<sub>2.5</sub> on mortality are based on cohort rather than time-series evidence because this enables years of life lost to be estimated. <sup>18</sup> However, most cohort evidence is from North America or Western Europe. Our finding that short-term associations occur worldwide supports the generalisation of cohort based estimates globally <sup>19</sup> while at the same time indicating that there may also be some heterogeneity.

Our study extends the literature reviewing the evidence for health effects of short-term exposure to PM<sub>2.5</sub> derived from time series studies. The numbers of single-city and multicity studies have increased substantially in recent years, from 55 in 2005<sup>11</sup> to 110 identified in this review. In 2009 the Environmental Protection Agency (EPA) summarised evidence from studies of mainly US populations<sup>5</sup> published between 2002 and May 2009. Also in 2009, the American Heart Association issued an updated statement on the effects of particulate air pollution on cardiovascular disease including evidence from time series studies published to March 2009.6 A more recent review in 20128 focused upon studies of PM<sub>2.5</sub> components indexed in the Science Citation Database up to October 2010. Our study complements these previous reviews by providing a meta-analysis for a much larger, more recent (indexed in medical databases to May 2011) and broader literature incorporating studies irrespective of geographical location and disease outcome.

Across the five WHO regions studied, our summary estimates for all-age, all-cause mortality ranged from 0.25% to 2.08% with an overall estimate of 1.04%, comparable with the summary estimate of 1.2% derived from seven studies by Levy et al.<sup>8</sup> While we found evidence of statistical heterogeneity across region-specific estimates both values are consistent with a mortality hazard from short-term exposure to fine particulate

Pooled single and multicity¶

1.00 (0.73 to 1.27)

	All-cause	Cardiovascula	r		Respiratory
No Adjustment*	1.04 (0.52 to 1.56)	0.84 (0.41 to 1	.28)		1.51 (1.01 to 2.01)
Single-city biast					
WHO region	Amr A	Amr A	Amr B	Eur A	Amr B
p Value Begg	0.14	0.57	0.32	0.35	0.32
p Value Egger	0.003	0.42	NA	0.32	NA
# Estimates	5	6	2	6	2
#Trim and fill	8	7	3	7	3
Single-city‡	0.97 (0.46 to 1.48)	0.78 (0.35 to 1	.21)		1.00 (0.73 to 1.27)
Multicity bias§					
p Value Begg	0.81	0.09			0.46
p Value Egger	0.36	0.32			0.52
# Estimates	8	6			8
# Trim and fill	8	8			8


<sup>\*</sup>Random effects summary estimate (95% CI) per  $10 \mu g/m^3$  without adjustment for small study bias.

0.57 (0.09 to 1.05)

0.97 (0.46 to 1.48)

matter. The reasons for this variability in effect estimates between WHO regions warrant further investigation but may reflect variations in population vulnerability and/or differential toxicity of sources, pollutant mixtures and pollution monitoring.

Our finding that the association for respiratory mortality (1.51%) was larger than for cardiovascular mortality (0.84%)—a finding observed within all WHO regions—was also reported by the EPA in their review. However, the EPA noted the coherence in associations between PM<sub>2.5</sub> and cardiovascular mortality and morbidity outcomes and the lack of such coherence for respiratory diseases. We were only able to assess the extent of coherence by comparing associations for mortality and admissions. For cardiovascular diseases our overall summary estimates for PM<sub>2.5</sub> and admissions and mortality were comparable confirming the coherence reported by the EPA although we note substantial disagreement between region-specific summary



**Figure 3** Funnel plot of pooled single-city and multi-city summary estimates for cardiovascular mortality including 'filled' estimates. Random effects summary estimates without (long-dash line) and with (short-dash line) adjustment using the Trim & Fill procedure.

estimates for each outcome including North America. We also note the negative, although statistically not significant, associations observed in three single-city studies in Europe and the Western Pacific region for hospital admissions for stroke in adults over the age of 65 years. For respiratory diseases, we found that the overall summary estimates for PM<sub>2.5</sub> and mortality and admissions were broadly comparable although for respiratory admissions the summary estimate was approximately two-thirds that for mortality and the CI for the summary estimate straddled 0% due to the negative association reported in a single-city study from North America. We note however that while the same ICD codes are used for mortality and admissions, the way they are used is different—underlying cause of death for the former and immediate cause of admission for the latter. This might affect comparability of certain categories such as pneumonia or heart failure though they would still fall within the broad cardiovascular or respiratory rubric.

The main strengths of our study are: (1) a protocol driven approach to the identification, coding and selection of effect estimates for meta-analysis to minimise selection bias throughout the review process; (2) inclusion of all health outcomes for which sufficient estimates were available for meta-analysis; (3) no limitations on study location or language, and (4) stratification of results by WHO region. However, in common with other reviews, our study is limited by: (1) the need for numerical, rather than graphical, presentation of data to facilitate quantitative meta-analysis; (2) the authors' choice of results to publish; and (3) having no assessment of the 'grey' literature. It is therefore important to assess the extent to which the inferences and quantitative estimates presented here have been affected by small study bias, a process that leads to the published literature being unrepresentative of the totality of evidence.<sup>20</sup>

Our analysis of small study effects, a generic term also encompassing publication bias and a range of other potential biases, <sup>21</sup> suggests that this may be an important issue in the meta-analysis of single-city and multicity estimates. The former has been noted previously in relation to time series studies of  $PM_{10}^{11}$  but the observation that meta-analysis of multicity estimates can be similarly affected is new. Sterne *et al* suggested that the greater

<sup>†</sup>Analysis of bias in single-city studies by WHO region (where found): Begg's test p value, Egger's test p value, number of estimates prior to application of 'trim and fill' technique, number of estimates after application of 'trim and fill' technique.

<sup>‡</sup>Overall summary estimate calculated after application of 'trim and fill' technique to single-city estimates by WHO region.

<sup>§</sup>Bias between pooled single-city estimates and multicity estimates, Begg's test p value, Egger's test p value, number of estimates prior to application of the trim and fill' technique, number of estimates after application of the 'trim and fill' technique.

<sup>¶</sup>Overall summary estimate after application of the 'trim and fill' technique to single-city estimates within WHO region and between pooled single-city estimates and multicity estimates.

investment of time and money in larger studies (such as multicity time-series studies) meant such studies would be more likely to be of high methodological quality and published even if their results are negative. Sterne *et al* also noted that the 'trim and fill' procedure detects 'missing' studies in a substantial proportion of meta-analyses, even in the absence of bias. Thus, there is a danger that the application of the procedure could mean adding and adjusting for non-existent studies in response to funnel plot asymmetry arising from nothing more than random variation. Our finding that the 'trim and fill' adjustment substantially reduced the magnitude and precision of the associations between PM<sub>2.5</sub> and cardiovascular mortality should therefore be interpreted with some caution, especially so given the unremarkable p values from the Begg and Egger tests and the funnel plot presented in figure 3.

Other potential sources of bias in our study methodology could be: (1) the selection of estimates from the individual papers; and (2) the selection of study estimates for meta-analysis. Bias arising from the former is possible given the tendency of investigators to assess associations at different time lags between exposure and health event. To address this we used a protocol for estimate selection that was independent of the direction of an association. In previous work this has been shown not to introduce bias but increase between-estimate heterogeneity<sup>11</sup> so we believe that it is unlikely that we are overstating the magnitude of associations. Our protocol for the selection of estimates (from those available) for meta-analysis similarly did not consider direction of associations, instead basing the selection upon geographical coverage, publication date and length of study period. It also ensured that no single location appeared more than once in a summary estimate. While our approach was just one of many analytical strategies that could have been adopted, we believe that the resulting summary estimates were unlikely to be systematically biased since none of our selection criteria included the direction or magnitude, of the individual study effect estimates. The relevance of these issues cannot be overstated since results from meta-analyses can be important in underpinning the use of more limited cohort data in worldwide health impact assessments.<sup>15</sup>

Our review points to adverse associations between short-term exposure to daily concentrations of PM<sub>2.5</sub> and daily mortality and hospital admissions across a range of diseases and age groups which supports continued policy measures to control PM<sub>2.5</sub> levels worldwide. However, we note that the evidence for these associations is concentrated in a small number of geographical regions of the world and also limited to the broader categories of disease. Further studies from other developed countries, in particular Asia and Eastern Europe, are needed to confirm the observed associations. Also, new studies including specific, rather than broad, categories of diseases would increase understanding of the populations at risk and may also add to our understanding of mechanism of effect. In addition, the reasons for the heterogeneity in effect estimates in different regions of the world require further research as they may be relevant to the formulation of policy measures. Our findings also suggest that, for the purpose of health impact assessment, some consideration of, and adjustment for, small study bias in results from multicity as well as single-city studies should be undertaken.

**Acknowledgements** This is independent research commissioned by the Policy Research Programme in the Department of Health. The views expressed are not necessarily those of the Department.

**Contributors** All authors contributed to the design of the study and to the drafting of the paper and have seen and approved the final version. Data analysis was carried out by RWA.

**Funding** Policy Research Programme in the Department of Health (002/0037).

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

#### REFERENCES

- 1 WHO. Air Quality Guidelines. Global Update 2005. Copenhagen: World Health Organisation Regional Office for Europe, 2006.
- WHO. Health relevance of particulate matter from various sources. Report on a WHO workshop Bonn, Germany 26–27 March 2007. http://www.euro.who.int/data/ assets/pdf file/0007/78658/E90672.pdf laccessed June 20101.
- 3 Health Effects Institute. Health Effects of Outdoor Air Pollution in Developing Countries of Asia: A Literature Review. Special Report 15, 2004.
- 4 Pope CA 3rd, Dockery DW. Health effects of fine particulate air pollution: lines that connect. *J Air Waste Manage Assoc* 2006;56:709–42.
- 5 U.S. EPA. Integrated Science Assessment for Particulate Matter (Final Report). U.S. Environmental Protection Agency, Washington, DC, EPA/600/R-08/139F, 2009. http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=216546#Download [accessed 15 June 2013].
- 6 Brook RD, Rajagopalan S, Pope CA III, et al. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation 2010;121:2331–78.
- 7 Ruckerl R, Schneider A, Breitner S, et al. Health effects of particulate air pollution: A review of epidemiological evidence. *Inhal Toxicol* 2011;23:555–92.
- 8 Levy JI, Diez D, Dou Y, et al. A meta-analysis and multisite time series analysis of the differential toxicity of major fine particulate matter constituents. Am J Epidemiol 2012:175:1091–9
- 9 WHO. Review of evidence on health aspects of air pollution—REVIHAAP Project: Final technical report. The WHO European Centre for Environment and Health, Bonn, 2013. http://www.euro.who.int/en/what-we-do/health-topics/environmentand-health/air-quality/publications/2013/review-of-evidence-on-health-aspects-ofair-pollution-revihaap-project-final-technical-report [accessed Aug 2013].
- 10 Shah ASV, Langrish JP, Nair H, et al. Global association of air pollution and heart failure: a systematic review and meta-analysis. Lancet 2013;382:1039–48. (online July 10, 2013). http://dx.doi.org/10.1016/S0140-6736(13)60898-3
- Department of Health. Quantitative systematic review of short term associations between ambient air pollution (particulate matter, ozone, nitrogen dioxide, sulphur dioxide and carbon monoxide), and mortality and morbidity. London: Department of Health, 2007. https://www.gov.uk/government/publications/quantitative-systematic-review-of-short-term-associations-between-ambient-air-pollution-particulate-matter-ozone-nitrogen-dioxide-sulphur-dioxide-and-carbon-monoxide-and-mortality-and-morbidity (accessed 15 Feb 2013).
- 12 Anderson HR, Atkinson RW, Peacock JL, et al. Ambient particulate matter and health effects—publication bias in studies of short-term associations. Epidemiol 2005;16:155–63.
- 13 DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
- Huedo-Medina TB, Sanchez-Meca J, Marın-Martinez F, et al. Assessing Heterogeneity in Meta-Analysis: Q Statistic or I<sup>2</sup> Index? Psychol Methods 2006;11:193–206.
- 15 Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst 1989:81:107–15.
- 16 Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
- Duval S, Tweedie R. A nonparametric "trim and fill" method of accounting for publication bias in meta-analysis. J Amer Statist Assoc 2000;95:89–98.
- Department of Health. The Mortality Effects of Long-Term Exposure to Particulate Air Pollution in the United Kingdom. 2010. Committee on the Medical Effects of Air Pollutants. http://www.hpa.orq.uk/webc/HPAwebFile/HPAweb\_C/1317137012567
- Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224–60.
- 20 Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev 1997;9:15–21.
- 21 Sterne JA, Egger M, Davey Smith G. Investigating and dealing with publication and other biases in meta-analyses. BMJ 2001;323:101–5.

# Epidemiological time series studies of PM<sub>2.5</sub> and daily mortality and hospital admissions – a systematic review and meta-analysis

RW Atkinson<sup>1</sup>, S Kang<sup>1</sup>, HR Anderson<sup>1,2</sup>, IC Mills<sup>3</sup>, HA Walton<sup>2,4</sup>

# **Supplementary Material**

#### **Contents**

## **Methods**

Search string

Study Selection criteria

Lag selection protocol

Estimate selection protocol

Publication bias analysis

# **Tables**

Table S1 List of countries by WHO Regions

Table S2 Grouping of ICD codes into disease groups

Table S3 Grouping of age ranges into age groups

Table S4 List of time series studies of PM<sub>2.5</sub> and mortality and hospital admissions

Table S5 Meta-analysis results for cause-specific mortality by WHO region and overall

Table S6 Meta-analysis results for ages 65+ years for cardiovascular admissions by WHO region and overall

Table S7 Meta-analysis results for ages 65+ and 0-14+ years for respiratory admissions by WHO region and overall

# **Figures**

Figure S1 Study and estimate details for all-cause mortality results selected for meta-analysis

Figure S2 Study and estimate details for cardiovascular mortality results selected for metaanalysis

Figure S3 Study and estimate details for respiratory mortality results selected for meta-analysis

Figure S4 Study and estimate details for IHD mortality results selected for meta-analysis

Figure S5 Study and estimate details for stroke mortality results selected for meta-analysis

Figure S6 Study and estimate details for COPD mortality results selected for meta-analysis

Figure S7 Study and estimate details for all-age, cardiovascular hospital admissions results selected for meta-analysis

Figure S8 Study and estimate details for 65+ years, cardiovascular hospital admissions results selected for meta-analysis

Figure S9 Study and estimate details for 65+ years, cardiac hospital admissions results selected for meta-analysis

Figure S10 Study and estimate details for 65+ years, IHD hospital admissions results selected for meta-analysis

Figure S11 Study and estimate details for 65+ years, stroke hospital admissions results selected for meta-analysis

Figure S12 Study and estimate details for 65+ years, heart failure hospital admissions results selected for meta-analysis

Figure S13 Study and estimate details for 65+ years, dysrhythmias hospital admissions results selected for meta-analysis

Figure S14 Study and estimate details for all-age, respiratory hospital admissions results selected for meta-analysis

Figure S15 Study and estimate details for 65+ years, respiratory hospital admissions results selected for meta-analysis

Figure S16 Study and estimate details for 65+ years, COPD including asthma hospital admissions results selected for meta-analysis

Figure S17 Study and estimate details for 65+ years, COPD excluding asthma hospital admissions results selected for meta-analysis

Figure S18 Study and estimate details for 65+ years, lower respiratory infections hospital admissions results selected for meta-analysis

Figure S19 Study and estimate details for ages 0-14 years, respiratory hospital admissions results selected for meta-analysis

Figure S20 Study and estimate details for ages 0-14 years, asthma hospital admissions results selected for meta-analysis

#### Methods

# **Search String**

The following search string was used (with minor amendments for the specific databases) to identify potential studies published in peer reviewed journals and indexed in <a href="PubMed">PubMed</a>, <a href="EMBASE">EMBASE</a> or <a href="Web of Science">Web of Science</a> (which includes the Science Citation Index):

(air pollution OR pollution OR smog OR particle\*OR particulate\*) AND (timeseries OR time series OR time-series OR daily OR case-crossover) AND (mortality OR death\* OR dying OR hospital admission\* OR admission\* OR emergency room OR visit\* OR attendance\* OR 'a&e' OR 'a and e' OR accident and emergency OR general pract\* OR physician\* OR consultation\* OR emergency department\*)

# **Study Selection criteria**

The selection criteria used were that the study provided: 1) estimates for  $PM_{2.5}$ ; 2) at least one year of daily data relating to a general population; 3) a reasonable attempt to control for important confounding factors such as season, long-term temporal trends and meteorological conditions and 4) sufficient information for the calculation of a regression estimate and standard error for comparison in the quantitative analysis. No limitation was placed upon language. We also cross-checked our search results against publications selected for other reviews.

# Lag selection protocol

The short-term relationships between air pollution and health effects are characterised by the time lag (in days) between exposure and health events and investigators vary in which lags they study and report. This means that the use of any particular lag would result in the exclusion of many other studies. In the absence of a standard method of reporting the lag, we therefore adopted the following approach for selecting lag results for inclusion in the database. If only one lagged estimate for a given pollutant/outcome pair was presented (either because only one was analysed or only one was reported in the paper), this estimate was recorded in the Access database for the outcome–pollutant pair. If more than one lag measure was presented, we selected one for meta-analysis according to the following algorithm: 1) the lag that the author focused on or stated a priori; 2) the lag that was the most statistically significant (positive or

negative) and 3) the lag with the largest effect estimate (positive or negative). For options 2) and 3) results for single lags were selected ahead of results for cumulative/distributed lags.

# **Estimate selection protocol**

Furthermore, numerous multi-city studies have incorporated the same cities more than once. Inclusion of results from a single-city more than once in a meta-analysis was not appropriate as the study populations will be correlated and the over-representation of a single-city may bias the summary estimate. Hence, we selected estimates from single-city studies only if they did not appear in multi-city studies. If a city was the subject of a single-city study on more than one occasion we took the result for the most recent publication. Where results from more than one multi-city study within a WHO Region were available we selected, in order of priority, the multi-city study: 1) with the most cities/greatest geographical coverage; 2) the most recently published; and 3) the longest study period.

# **Table S1 List of countries by WHO Region and mortality strata** (Source: *The World Health Report 2002*)

# **Mortality strata**

A. Very low child, very low adult B. Low child, low adult

C. Low child, high adult

D. High child, high adult

E. High child, very high adult

Eastern Mediterranean Region	European Region	Region of the Americas	South-East Asian Region	Western Pacific Region
EMR B	EUR A	AMR A	SEAR B	WPR A
<ul> <li>Bahrain</li> <li>Cyprus</li> <li>Iran, Islamic Republic of</li> <li>Jordan</li> <li>Kuwait</li> <li>Lebanon</li> </ul>	<ul> <li>Andorra</li> <li>Austria</li> <li>Belgium</li> <li>Croatia</li> <li>Czech Republic</li> <li>Denmark</li> <li>Finland</li> </ul>	<ul><li>Canada</li><li>Cuba</li><li>United States of America</li></ul> AMR B	<ul> <li>Indonesia</li> <li>Sri Lanka</li> <li>Thailand</li> <li>Timor-Leste</li> </ul> SEAR D	<ul> <li>Australia</li> <li>Brunei     Darussalam</li> <li>Japan</li> <li>New Zealand</li> <li>Singapore</li> </ul>
<ul> <li>Libyan Arab Jamahiriya Oman Qatar Saudi Arabia </li> </ul>	<ul><li>France</li><li>Germany</li><li>Greece</li><li>Iceland</li><li>Ireland</li></ul>	<ul> <li>Antigua and Barbuda</li> <li>Argentina</li> <li>Bahamas</li> <li>Barbados</li> </ul>	<ul> <li>Bangladesh</li> <li>Bhutan</li> <li>Democratic People's Republic of</li> </ul>	<ul> <li>WPR B</li> <li>Cambodia</li> <li>China</li> <li>Cook Islands</li> <li>Fiji</li> </ul>
	Mediterranean Region  EMR B  Bahrain Cyprus Iran, Islamic Republic of Jordan Kuwait Lebanon Libyan Arab Jamahiriya Oman Qatar	Mediterranean Region  EMR B  Bahrain Cyprus Iran, Islamic Republic of Jordan Kuwait Lebanon Libyan Arab Jamahiriya Oman Qatar Saudi Arabia Region  EUR A  Andorra Austria Caustria Croatia Croatia Czech Republic Czech Republic France Caustria Czech Republic Czech	Mediterranean RegionEUR AAMR AEMR BEUR AAMR ABahrain • Cyprus • Iran, Islamic Republic of • Jordan • Kuwait • Lebanon • Libyan Arab Jamahiriya • Oman • Qatar • Saudi Arabia• Andorra • Austria • Belgium • Croatia • Croatia • Croatia • Croatia • Croatia • Croatia • Croatia • Croatia • Croatia • Croatia 	Mediterranean RegionEUR AAMR ASEAR B• Bahrain • Cyprus • Iran, Islamic Republic of • Jordan • Lebanon • Libyan Arab Jamahiriya • Oman • Qatar • Saudi Arabia• Andorra • Andorra • Austria • Canada • Cuba • Cuba • United States • Of America• Indonesia • Sri Lanka • United States • Of America• Lobanon • Finland • France • Qatar • Saudi Arabia• AMR BSEAR D• Antigua and • Antigua and • Argentina • Bangladesh • Bahamas • Bahamas • Barbados• Bengladesh • Bhutan • Democratic • People's • Republic of

<ul><li>Guinea-Bissau</li><li>Liberia</li><li>Madagascar</li></ul>	Republic     Tunisia     United Arab	<ul><li>Italy</li><li>Luxembourg</li><li>Malta</li></ul>	<ul> <li>Brazil</li> <li>Chile</li> <li>Colombia</li> <li>India</li> <li>Maldives</li> <li>Myanmar</li> </ul>	<ul><li>Kiribati</li><li>Lao People's Democratic</li></ul>
<ul> <li>Mali</li> <li>Mauritania</li> <li>Mauritius</li> <li>Niger</li> <li>Nigeria</li> <li>Sao Tome and Principe</li> <li>Senegal</li> <li>Seychelles</li> <li>Sierra Leone</li> <li>Togo</li> </ul>	Emirates  EMR D  Afghanistan Djibouti Egypt Iraq Morocco Pakistan Somalia	<ul> <li>Monaco</li> <li>Netherlands</li> <li>Norway</li> <li>Portugal</li> <li>San Marino</li> <li>Slovenia</li> <li>Spain</li> <li>Sweden</li> <li>Switzerland</li> <li>United Kingdom</li> </ul>	<ul> <li>Costa Rica</li> <li>Dominica</li> <li>Dominican Republic</li> <li>El Salvador</li> <li>Grenada</li> <li>Guyana</li> <li>Honduras</li> <li>Jamaica</li> <li>Mexico</li> <li>Panama</li> </ul>	Republic  Malaysia  Marshall Islands  Micronesia, Federated States of  Mongolia  Nauru  Niue Palau
<ul> <li>AFR E</li> <li>Botswana</li> <li>Burundi</li> <li>Central African Republic</li> <li>Congo</li> <li>Côte d'Ivoire</li> <li>Democratic Republic of Congo</li> <li>Eritrea</li> <li>Ethiopia</li> <li>Kenya</li> <li>Lesotho</li> <li>Malawi</li> <li>Mozambique</li> </ul>	• Sudan • Yemen	<ul> <li>Albania</li> <li>Armenia</li> <li>Azerbaijan</li> <li>Bosnia and Herzegovina</li> <li>Bulgaria</li> <li>Georgia</li> <li>Kyrgyzstan</li> <li>Poland</li> <li>Romania</li> <li>Slovakia</li> <li>Tajikistan</li> <li>The former Yugoslav Republic of</li> </ul>	<ul> <li>Paraguay</li> <li>Saint Kitts and Nevis</li> <li>Saint Lucia</li> <li>Saint Vincent and the Grenadines</li> <li>Suriname</li> <li>Trinidad and Tobago</li> <li>Uruguay</li> <li>Venezuela, Bolivarian Republic of</li> </ul> AMR D <ul> <li>Bolivia</li> </ul>	<ul> <li>Papua New Guinea</li> <li>Philippines</li> <li>Republic of Korea</li> <li>Samoa</li> <li>Solomon Islands</li> <li>Tonga</li> <li>Tuvalu</li> <li>Vanuatu</li> <li>Viet Nam</li> </ul>

<ul> <li>Namibia</li> <li>Rwanda</li> <li>South Africa</li> <li>Swaziland</li> <li>Uganda</li> <li>United Republic of Tanzania</li> <li>Zambia</li> <li>Zimbabwe</li> </ul>	Macedonia     Turkey     Turkmenistan     Uzbekistan     Yugoslavia  EUR C      Belarus     Estonia     Hungary     Kazakhstan     Latvia     Lithuania     Republic of Moldova     Russian     Federation     Ukraine	<ul> <li>Ecuador</li> <li>Guatemala</li> <li>Haiti</li> <li>Nicaragua</li> <li>Peru</li> </ul>	
---	--	--	--

Source: http://www.who.int/choice/demography/regions/en/ (accessed 27th March 2014)

# Table S2 List of time series studies of PM<sub>2.5</sub> and mortality and hospital admissions

Goldberg, M.S., Burnett, R.T., Bailar, J.C., Brook, J., Bonvalot, Y., Tamblyn, R., Singh, R., & Valois, M.F. 2001. The association between daily mortality and ambient air particle pollution in Montreal, Quebec 1. Nonaccidental mortality. *Environmental Research*, 86, (1) 12-25 Ref ID: 19

Burnett, R.T., Smith-Doiron, M., Stieb, D., Raizenne, M.E., Brook, J.R., Dales, R.E., Leech, J.A., Cakmak, S., & Krewski, D. 2001. Association between ozone and hospitalization for acute respiratory diseases in children less than 2 years of age. *American Journal of Epidemiology*, 153, (5) 444-452

Ref ID: 57

Anderson, H.R., Bremner, S.A., Atkinson, R.W., Harrison, R.M., & Walters, S. 2001. Particulate matter and daily mortality and hospital admissions in the west midlands conurbation of the United Kingdom: associations with fine and coarse particles, black smoke and sulphate. *Occupational and Environmental Medicine*, 58, (8) 504-510

Ref ID: 69

Chen, Y., Yang, Q.Y., Krewski, D., Burnett, R.T., Shi, Y.L., & McGrail, K.M. 2005. The effect of coarse ambient particulate matter on first, second, and overall hospital admissions for respiratory disease among the elderly. *Inhalation Toxicology*, 17, (12) 649-655 available from: ISI:000231082600002

Ref ID: 73

Ostro, B., Roth, L., Malig, B., & Marty, M. 2009. The Effects of Fine Particle Components on Respiratory Hospital Admissions in Children. *Environmental Health Perspectives*, 117, (3) 475-480 available from: ISI:000263933600038 Ref ID: 95

Chimonas, M.A.R. & Gessner, B.D. 2007. Airborne particulate matter from primarily geologic, non-industrial sources at levels below National Ambient Air Quality Standards is associated with outpatient visits for asthma and quick-relief medication prescriptions among children less than 20 years old enrolled in Medicaid in Anchorage, Alaska. *Environmental Research*, 103, (3) 397-404 available from: ISI:000244903200014 Ref ID: 100

Lin, M., Chen, Y., Burnett, R.T., Villeneuve, P.J., & Krewski, D. 2002. The influence of ambient coarse particulate matter on asthma hospitalization in children: Case-crossover and time series analyses. *Environmental Health Perspectives*, 110, (6) 575-581
Ref ID: 103

Zanobetti, A. & Schwartz, J. 2006. Air pollution and emergency admissions in Boston, MA. *Journal of Epidemiology and Community Health*, 60, (10) 890-895 available from: ISI:000240495000015

Ref ID: 105

Lee, S.L., Wong, W.H.S., & Lau, Y.L. 2006. Association between air pollution and asthma admission among children in Hong Kong. *Clinical and Experimental Allergy*, 36, (9) 1138-1146 available from: ISI:000240311900005

Ref ID: 126

Simpson, R., Williams, G., Petroeschevsky, A., Best, T., Morgan, G., Denison, L., Hinwood, A., Neville, G., & Neller, A. 2005. The short-term effects of air pollution on daily mortality in four Australian cities. *Australian and New Zealand Journal of Public Health*, 29, (3) 205-212 available

from: ISI:000229854700003

Ref ID: 133

Burnett, R.T., Brook, J., Dann, T., Delocla, C., Philips, O., Cakmak, S., Vincent, R., Goldberg, M.S., & Krewski, D. 2000. Association between particulate- and gas-phase components of urban air pollution and daily mortality in eight Canadian cities. *Inhalation Toxicology*, 12, 15-39 Ref ID: 135

Moolgavkar, S.H. 2000. Air pollution and hospital admissions for chronic obstructive pulmonary disease in three metropolitan areas in the United States. *Inhalation Toxicology*, 12, 75-90 Ref ID: 136

Ostro, B.D., Broadwin, R., & Lipsett, M.J. 2000. Coarse and fine particles and daily mortality in the Coachella Valley, California: a follow-up study. *Journal of Exposure Analysis and Environmental Epidemiology*, 10, (5) 412-419

Ref ID: 144

Kan, H., Jia, J., & Chen, B.H. 2004. The association of daily diabetes mortality and outdoor air pollution in Shanghai, China. *Journal of Environmental Health*, 67, (3) 21-25 available from: ISI:000224044900004

Ref ID: 150

Ito, K., Christensen, W.F., Eatough, D.J., Henry, R.C., Kim, E., Laden, F., Lall, R., Larson, T.V., Neas, L., Hopke, P.K., & Thurston, G.D. 2006. PM source apportionment and health effects: 2. An investigation of intermethod variability in associations between source-apportioned fine particle mass and daily mortality in Washington, DC. *Journal of Exposure Science and Environmental Epidemiology*, 16, (4) 300-310 available from: ISI:000239389600002 Ref ID: 159

Moolgavkar, S.H. 2003. Air pollution and daily mortality in two U. S. counties: Season-specific analyses and exposure-response relationships. *Inhalation Toxicology*, 15, (9) 877-907 available from: ISI:000184470900002

Ref ID: 162

Moolgavkar, S.H. 2000. Air pollution and daily mortality in three US counties. *Environmental Health Perspectives*, 108, (8) 777-784

Ref ID: 163

Klemm, R.J. & Mason, R.M. 2000. Aerosol Research and Inhalation Epidemiological Study (ARIES): Air quality and daily mortality statistical modeling - Interim results. *Journal of the Air & Waste Management Association*, 50, (8) 1433-1439
Ref ID: 176

Chock, D.P. & Winkler, S.L. 2000. A study of the association between daily mortality and ambient air pollutant concentrations in Pittsburgh, Pennsylvania. *Journal of the Air & Waste Management Association*, 50, (8) 1481-1500

Ref ID: 177

Lipfert, F.W., Morris, S.C., & Wyzga, R.E. 2000. Daily mortality in the Philadelphia metropolitan area and size- classified particulate matter. *Journal of the Air & Waste Management Association*, 50, (8) 1501-1513

Ref ID: 178

Loomis, D.P., Castillejos, M., Gold, D.R., McDonnell, W., & Borja-Aburto, V.H. 1999. Air pollution and infant mortality in Mexico City. *Epidemiology*, 10, (2) 118-123 Ref ID: 210

Peters, A., Skorkovsky, J., Kotesovec, F., Brynda, J., Spix, C., Wichmann, H.E., & Heinrich, J. 2000. Associations between mortality and air pollution in Central Europe. *Environmental Health Perspectives*, 108, (4) 283-287

Ref ID: 212

Borja-Aburto, V.H., Castillejos, M., Gold, D.R., Bierzwinski, S., & Loomis, D. 1998. Mortality and ambient fine particles in southwest Mexico City, 1993-1995. *Environmental Health Perspectives*, 106, (12) 849-855

Ref ID: 214

Burnett, R.T., Cakmak, S., Raizenne, M.E., Stieb, D., Vincent, R., Krewski, D., Brook, J.R., Philips, O., & Ozkaynak, H. 1998. The association between ambient carbon monoxide levels and daily mortality in Toronto, Canada. *Journal of the Air & Waste Management Association*, 48, (8) 689-700

Ref ID: 224

Slaughter, J.C., Kim, E., Sheppard, L., Sullivan, J.H., Larson, T.V., & Claiborn, C. 2005. Association between particulate matter and emergency room visits, hospital admissions and mortality in Spokane, Washington. *Journal of Exposure Analysis and Environmental Epidemiology*, 15, (2) 153-159 available from: ISI:000227541800005

Ref ID: 230

Halonen, J.I., Lanki, T., Yli-Tuomi, T., Tiittanen, P., Kulmala, M., & Pekkanen, J. 2009. Particulate Air Pollution and Acute Cardiorespiratory Hospital Admissions and Mortality Among the Elderly. *Epidemiology*, 20, (1) 143-153 available from: ISI:000261930800023 Ref ID: 238

Schreuder, A.B., Larson, T.V., Sheppard, L., & Claiborn, C.S. 2006. Ambient woodsmoke and associated respiratory emergency department visits in Spokane, Washington. *International Journal of Occupational and Environmental Health*, 12, (2) 147-153 available from: <a href="ISI:000237477200008">ISI:000237477200008</a>

Ref ID: 239

Cancado, J.E., Saldiva, P.H.N., Pereira, L.A.A., Lara, L.B.L.S., Artaxo, P., Martinelli, L.A., Arbex, M.A., Zanobetti, A., & Braga, A.L.F. 2006. The impact of sugar cane-burning emissions on the respiratory system of children and the elderly. *Environmental Health Perspectives*, 114, (5) 725-729 available from: ISI:000237308500040 Ref ID: 248

Schwartz, J., Dockery, D.W., & Neas, L.M. 1996. Is daily mortality associated specifically with fine particles? *Journal of the Air & Waste Management Association*, 46, (10) 927-939 Ref ID: 250

Ostro, B.D. 1995. Fine particulate air pollution and mortality in two Southern California counties. *Environmental Research*, 70, (2) 98-104 Ref ID: 271

Perez, L., Tobias, A., Querol, X., Kunzli, N., Pey, J., Alastuey, A., Viana, M., Valero, N., Gonzalez-Cabre, M., & Sunyer, J. 2008. Coarse Particles From Saharan Dust and Daily Mortality.

*Epidemiology*, 19, (6) 800-807 available from: ISI:000260191700009 Ref ID: 283

Dockery, D.W., Schwartz, J., & Spengler, J.D. 1992. Air pollution and daily mortality: associations with particulates and acid aerosols. *Environmental Research*, 59, (2) 362-373 Ref ID: 312

Lisabeth, L.D., Escobar, J.D., Dvonch, J.T., Sanchez, B.N., Majersik, J.J., Brown, D.L., Smith, M.A., & Morgenstern, L.B. 2008. Ambient air pollution and risk for ischemic stroke and transient ischemic attack. *Annals of Neurology*, 64, (1) 53-59 available from: ISI:000258199900009 Ref ID: 333

Burnett, R.T., Smith-Doiron, M., Stieb, D., Cakmak, S., & Brook, J.R. 1999. Effects of particulate and gaseous air pollution on cardiorespiratory hospitalizations. *Archives of Environmental Health*, 54, (2) 130-139

Ref ID: 368

Sheppard, L., Levy, D., Norris, G., Larson, T.V., & Koenig, J.Q. 1999. Effects of ambient air pollution on nonelderly asthma hospital admissions in Seattle, Washington, 1987-1994. *Epidemiology*, Vol 10, (1) 23-30

Ref ID: 374

Ostro, B., Broadwin, R., Green, S., Feng, W.Y., & Lipsett, M. 2006. Fine particulate air pollution and mortality in nine California counties: Results from CALFINE. *Environmental Health Perspectives*, 114, (1) 29-33 available from: ISI:000234396800034 Ref ID: 379

Hinwood, A.L., De Klerk, N., Rodriguez, C., Jacoby, P., Runnion, T., Rye, P., Landau, L., Murray, F., Feldwick, M., & Spickett, J. 2006. The relationship between changes in daily air pollution and hospitalizations in Perth, Australia 1992-1998: A case-crossover study. *International Journal of Environmental Health Research*, 16, (1) 27-46 available from: ISI:000234228900004 Ref ID: 388

Ueda, K., Nitta, H., & Ono, M. 2009. Effects of fine particulate matter on daily mortality for specific heart diseases in Japan. *Circulation Journal*, 73, (7) 1248-1254 available from: ISI:000267584400016

Ref ID: 390

Peng, R.D., Chang, H.H., Bell, M.L., McDermott, A., Zeger, S.L., Samet, J.M., & Dominici, F. 2008. Coarse particulate matter air pollution and hospital admissions for cardiovascular and respiratory diseases among medicare patients. *Jama-Journal of the American Medical Association*, 299, (18) 2172-2179 available from: <a href="ISI:000255790000024">ISI:000255790000024</a> Ref ID: 391

Koop, G. & Tole, L. 2004. Measuring the health effects of air pollution: to what extent can we really say that people are dying from bad air? *Journal of Environmental Economics and Management*, 47, (1) 30-54 available from: ISI:000187570600003 Ref ID: 396

Burnett, R.T., Cakmak, S., Brook, J.R., & Krewski, D. 1997. The role of particulate size and chemistry in the association between summertime ambient air pollution and hospitalization for cardiorespiratory diseases. *Environmental Health Perspectives*, 105, (6) 614-620 Ref ID: 399

Delfino, R.J., Murphy-Moulton, A.M., Burnett, R.T., Brook, J.R., & Becklake, M.R. 1997. Effects of air pollution on emergency room visits for respiratory illnesses in Montreal, Quebec. *American Journal of Respiratory & Critical Care Medicine*, 155, (2) 568-576
Ref ID: 408

Cakmak, S., Dales, R.E., & Blanco, C. 2009. Components of particulate air pollution and mortality in Chile. *International Journal of Occupational and Environmental Health*, 15, (2) 152-158 available from: ISI:000266257200006 Ref ID: 412

Thurston, G.D., Ito, K., Hayes, C.G., Bates, D.V., & Lippmann, M. 1994. Respiratory hospital admissions and summertime haze air pollution in Toronto, Ontario: Consideration of the role of acid aerosols. *Environmental Research*, 65, (2) 271-290 Ref ID: 441

Jalaludin, B., Morgan, G., Lincoln, D., Sheppeard, V., Simpson, R., & Corbett, S. 2006. Associations between ambient air pollution and daily emergency department attendances for cardiovascular disease in the elderly (65 + years), Sydney, Australia. *Journal Of Exposure Science & Environmental Epidemiology*, 16, (3) 225-237 Ref ID: 449

Bell, M.L., Levy, J.K., & Lin, Z. 2008. The effect of sandstorms and air pollution on cause-specific hospital admissions in Taipei, Taiwan. *Occupational and Environmental Medicine*, 65, (2) 104-111 available from: ISI:000252601700005 Ref ID: 458

Neuberger, M., Rabczenko, D., & Moshammer, H. 2007. Extended effects of air pollution on cardiopulmonary mortality in Vienna. *Atmospheric Environment*, 41, (38) 8549-8556 available from: ISI:000252101300012 Ref ID: 475

Brook, J.R., Burnett, R.T., Dann, T.F., Cakmak, S., Goldberg, M.S., Fan, X.H., & Wheeler, A.J. 2007. Further interpretation of the acute effect of nitrogen dioxide observed in Canadian time series studies. *Journal of Exposure Science and Environmental Epidemiology*, 17, S36-S44 available from: ISI:000251751900006

Ref ID: 485

Atkinson, R.W., Fuller, G.W., Anderson, H.R., Harrison, R.M., & Armstrong, B. 2010. Urban ambient particle metrics and health: a time series analysis. *Epidemiology*, 21, (4) 501-511 Ref ID: 517

Belleudi, V., Faustini, A., Stafoggia, M., Cattani, G., Marconi, A., Perucci, C.A., & Forastiere, F. 2010. Impact of fine and ultrafine particles on emergency hospital admissions for cardiac and respiratory diseases. *Epidemiology*, 21, (3) 414-423 Ref ID: 520

Sanhueza, P., Vargas, C., & Jimenez, J. 1999. Daily mortality in Santiago and its relationship with air pollution. *Revista Medica de Chile*, 127, (NO- 2) 235-242 Ref ID: 530

Ko, F.W.S., Tam, W., Wong, T.W., Lai, C.K.W., Wong, G.W.K., Leung, T.F., Ng, S.S.S., & Hui, D.S.C. 2007. Effects of air pollution on asthma hospitalization rates in different age groups in Hong Kong. *Clinical and Experimental Allergy*, 37, (9) 1312-1319 available from:

ISI:000249253100008

Ref ID: 567

Jimenez, E., Linares, C., Rodriguez, L.F., Bleda, M.J., & Diaz, J. 2009. Short-term impact of particulate matter (PM2.5) on daily mortality among the over-75 age group in Madrid (Spain). *Science of the Total Environment*, 407, (21) 5486-5492 Ref ID: 576

Jimenez, E., Linares, C., Martinez, D., & Diaz, J. 2010. Role of Saharan dust in the relationship between particulate matter and short-term daily mortality among the elderly in Madrid (Spain). *Science of the Total Environment*, 408, (23) 5729-5736
Ref ID: 577

Linares, C. & Diaz, J. 2010. Short-term effect of concentrations of fine particulate matter on hospital admissions due to cardiovascular and respiratory causes among the over-75 age group in Madrid, Spain. *Public Health*, 124, (1) 28-36 Ref ID: 590

Peng, R.D., Bell, M.L., Geyh, A.S., McDermott, A., Zeger, S.L., Samet, J.M., & Dominici, F. 2009. Emergency admissions for cardiovascular and respiratory diseases and the chemical composition of fine particle air pollution. *Environmental Health Perspectives*, 117, (6) 957-963 Ref ID: 618

Peters, A., Breitner, S., Cyrys, J., Stolzel, M., Pitz, M., Wolke, G., Heinrich, J., Kreyling, W., Kuchenhoff, H., & Wichmann, H. E. 2009, *The influence of improved air quality on mortality risks in Erfurt, Germany*.

Ref ID: 621

Ueda, K., Nitta, H., Ono, M., & Takeuchi, A. 2009. Estimating mortality effects of fine particulate matter in Japan: a comparison of time series and case-crossover analyses. *Journal of the Air & Waste Management Association*, 59, (10) 1212-1218
Ref ID: 669

Zanobetti, A. & Schwartz, J. 2009. The effect of fine and coarse particulate air pollution on mortality: a national analysis. *Environmental Health Perspectives*, 117, (6) 898-903 Ref ID: 684

Jayaraman, G. & Nidhi 2008. Air pollution and associated respiratory morbidity in Delhi. *Health Care Management Science*, 11, (2) 132-138 available from:

http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=18581819&site=ehost-live

Ref ID: 739

Fairley, D. 1999. Daily mortality and air pollution in Santa Clara County, California: 1989-1996. *Environmental Health Perspectives*, 107, (8) 637-641 Ref ID: 889

Huang, W., Tan, J., Kan, H., Zhao, N., Song, W., Song, G., Chen, G., Jiang, L., Jiang, C., Chen, R., & Chen, B. 2009. Visibility, air quality and daily mortality in Shanghai, China. *The Science Of The Total Environment*, 407, (10) 3295-3300 available from:

http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=19275954&site=ehost-live

Ref ID: 923

Castillejos, M., BorjaAburto, V.H., Dockery, D.W., Gold, D.R., & Loomis, D. 2000. Airborne coarse particles and mortality. *Inhalation Toxicology*, 12, 61-72 Ref ID: 1075

Mar, T.F., Norris, G.A., Koenig, J.Q., & Larson, T.V. 2000. Associations between air pollution and mortality in Phoenix, 1995- 1997. *Environmental Health Perspectives*, 108, 347-353 Ref ID: 1120

Cifuentes, L., Vega, J., Kopfer, K., & Lava, L.B. 2000. Effect of the fine fraction of particulate matter versus the coarse mass and other pollutants on daily mortality in Santiago, Chile. *Journal of the Air & Waste Management Association*, 50, (8) 1287-1298
Ref ID: 1152

Lippmann, M., Ito, K., Nadas, A., & Burnett, R. T. 2000, *Association of particulate matter components with daily mortality and morbidity in urban populations*, Health Effects Institute, 95. Ref ID: 1181

Samet, J. M., Zeger, S. L., Dominici, F., Curriero, F., Coursac, I., Dockery, D. W., Schwartz, J., & Zanobetti, A. 2000, *The national morbidity, mortality and air pollution study part II:morbidity, mortality and air pollution in the United States*, Health Effects Institute, 94, Part II. Ref ID: 1182

Moolgavkar, S.H. 2000. Air pollution and hospital admissions for diseases of the circulatory system in three US metropolitan areas. *Journal of the Air & Waste Management Association*, 50, (7) 1199-1206
Ref ID: 1196

Wichmann, H. E., Spix, C., Tuch, T., Wolke, G., Peters, A., Heinrich, J., Kreyling, W. G., & Heyder, J. 2000, *Daily Mortality and Fine and Ultrafile Particles in Erfurt, Germany Part I: Role of Particle Number and Particle Mass*, Health Effects Institute, 98. Ref ID: 1205

Goldberg, M.S., Burnett, R.T., Bailar, J.C., Brook, J., Bonvalot, Y., Tamblyn, R., Singh, R., Valois, M.F., & Vincent, R. 2001. The association between daily mortality and ambient air particle pollution in Montreal, Quebec 2. Cause-specific mortality. *Environmental Research*, 86, (1) 26-36 Ref ID: 1347

Schwartz, J., Laden, F., & Zanobetti, A. 2002. The concentration-response relation between PM(2.5) and daily deaths. *Environmental Health Perspectives.*, 110, (10) 1025-1029 Ref ID: 1481

2003, Revised analyses of time series studies of air pollution and health, Health Effects Institute, Special report.

Ref ID: 1494

Venners, S.A., Wang, B.Y., Peng, Z.G., Xu, Y., Wang, L.H., & Xu, X.P. 2003. Particulate matter, sulfur dioxide, and daily mortality in Chongqing, China. *Environmental Health Perspectives*, 111, (4) 562-567 available from: ISI:000182144300048 Ref ID: 1497

Chen, Y., Yang, Q.Y., Krewski, D., Shi, Y., Burnett, R.T., & McGrail, K. 2004. Influence of relatively low level of particulate air pollution on hospitalization for COPD in elderly people. *Inhalation Toxicology*, 16, (1) 21-25 available from: ISI:000188240300002

Ref ID: 1506

Villeneuve, P.J., Burnett, R.T., Shi, Y.L., Krewski, D., Goldberg, M.S., Hertzman, C., Chen, Y., & Brook, J. 2003. A time series study of air pollution, socioeconomic status, and mortality in Vancouver, Canada. *Journal of Exposure Analysis and Environmental Epidemiology*, 13, (6) 427-435 available from: ISI:000186454100002

Ref ID: 1587

Holloman, C.H., Bortnick, S.M., Morara, M., Strauss, W.J., & Calder, C.A. 2004. A Bayesian hierarchical approach for relating PM2.5 exposure to cardiovascular mortality in North Carolina. *Environmental Health Perspectives*, 112, (13) 1282-1288 available from: ISI:000224547000027

Ref ID: 1607

Klemm, R.J., Lipfert, F.W., Wyzga, R.E., & Gust, C. 2004. Daily mortality and air pollution in Atlanta: Two years of data from ARIES. *Inhalation Toxicology*, 16, 131-141 available from: ISI:000222605700014

Ref ID: 1610

Dai, H., Weimin, S., Xiang, G., & Limin, C. 2004. Study on relationship between ambient PM10, PM2.5 pollution and daily mortality in a district in Shanghai. *Journal of Hygiene Research*, 33, (3) 293-296

Ref ID: 1642

Barnett, A.G., Williams, G.M., Schwartz, J., Best, T.L., Neller, A.H., Petroeschevsky, A.L., & Simpson, R.W. 2006. The effects of air pollution on hospitalizations for cardiovascular disease in elderly people in Australian and New Zealand cities. *Environmental Health Perspectives*, 114, (7) 1018-1023 available from: ISI:000239035100031

Ref ID: 1647

Chan, C.C., Chuang, K.J., Chien, L.C., Chen, W.J., & Chang, W.T. 2006. Urban air pollution and emergency admissions for cerebrovascular diseases in Taipei, Taiwan. *European Heart Journal*, 27, (10) 1238-1244 available from: ISI:000237319700019

Ref ID: 1650

Dominici, F., Peng, R.D., Bell, M.L., Pham, L., McDermott, A., Zeger, S.L., & Samet, J.M. 2006. Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. *Jama-Journal of the American Medical Association*, 295, (10) 1127-1134 available from: ISI:000235822500020

Ref ID: 1654

Fung, K.Y., Khan, S., Krewski, D., & Chen, Y. 2006. Association between air pollution and multiple respiratory hospitalizations among the elderly in Vancouver, Canada. *Inhalation Toxicology*, 18, (13) 1005-1011 available from: ISI:000240435400001

Ref ID: 1656

Babin, S.M., Burkom, H.S., Holtry, R.S., Tabernero, N.R., Stokes, L.D., vies-Cole, J.O., DeHaan, K., & Lee, D.H. 2007. Pediatric patient asthma-related emergency department visits and admissions in Washington, DC, from 2001-2004, and associations with air quality, socio-economic status and age group. *Environmental Health: A Global Access Science Source*, 6, 9 Ref ID: 1683

Franklin, M., Zeka, A., & Schwartz, J. 2007. Association between PM2.5 and all-cause and specific-cause mortality in 27 US communities. *Journal of Exposure Science and Environmental Epidemiology*, 17, (3) 279-287 available from: ISI:000246561100007 Ref ID: 1689

Kan, H., London, S.J., Chen, G.H., Zhang, Y.H., Song, G.X., Zhao, N.Q., Jiang, L.L., & Chen, B.H. 2007. Differentiating the effects of fine and coarse particles on daily mortality in Shanghai, China. *Environment International*, 33, (3) 376-384 available from: ISI:000245369400012 Ref ID: 1691

Kettunen, J., Lanki, T., Tiittanen, P., Aalto, P.P., Koskentalo, T., Kulmala, M., Salomaa, V., & Pekkanen, J. 2007. Associations of fine and ultrafine particulate air pollution with stroke mortality in an area of low air pollution levels. *Stroke*, 38, (3) 918-922 available from: ISI:000244482500024

Ref ID: 1692

Ostro, B., Feng, W.Y., Broadwin, R., Green, S., & Lipsett, M. 2007. The effects of components of fine particulate air pollution on mortality in California: Results from CALFINE. *Environmental Health Perspectives*, 115, (1) 13-19 available from: ISI:000243299200026 Ref ID: 1698

Ko, F.W., Tam, W., Wong, T.W., Chan, D.P., Tung, A.H., Lai, C.K., & Hui, D.S. 2007. Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. *Thorax*, 62, (9) 780-785
Ref ID: 1939

Andersen, Z.J., Wahlin, P., Raaschou-Nielsen, O., Ketzel, M., Scheike, T., & Loft, S. 2008. Size distribution and total number concentration of ultrafine and accumulation mode particles and hospital admissions in children and the elderly in Copenhagen, Denmark. *Occupational and Environmental Medicine*, 65, (7) 458-466 available from: ISI:000256890100005 Ref ID: 1950

Bell, M.L., Ebisu, K., Peng, R.D., Walker, J., Samet, J.M., Zeger, S.L., & Dominici, F. 2008. Seasonal and Regional Short-term Effects of Fine Particles on Hospital Admissions in 202 US Counties, 1999-2005. *American Journal of Epidemiology*, 168, (11) 1301-1310 available from: ISI:000261279600010

Ref ID: 1952

Breitner, S., Stolzel, M., Cyrys, J., Pitz, M., Wolke, G., Kreyling, W., Kuchenhoff, H., Heinrich, J., Wichmann, H.E., & Peters, A. 2009. Short-Term Mortality Rates during a Decade of Improved Air Quality in Erfurt, Germany. *Environmental Health Perspectives*, 117, (3) 448-454 available from: ISI:000263933600034

Ref ID: 1954

Cho, Y.S., Lee, J.T., Jung, C.H., Chun, Y.S., & Kim, Y.S. 2008. Relationship between particulate matter measured by optical particle counter and mortality in Seoul, Korea, during 2001. *Journal of Environmental Health*, 71, (2) 37-43 available from: ISI:000259122900006 Ref ID: 1958

Franklin, M., Koutrakis, P., & Schwartz, J. 2008. The role of particle composition on the association between PM2.5 and mortality. *Epidemiology*, 19, (5) 680-689 available from: ISI:000258712000009

Ref ID: 1961

Host, S., Larrieu, S., Pascal, L., Blanchard, M., Declercq, C., Fabre, P., Jusot, J.F., Chardon, B., Le Tertre, A., Wagner, V., Prouvost, H., & Lefranc, A. 2008. Short-term associations between fine and coarse particles and hospital admissions for cardiorespiratory diseases in six French cities. *Occupational and Environmental Medicine*, 65, (8) 544-551 available from:

ISI:000257885200006

Ref ID: 1968

Mukamal, K.J., Wellenius, G.A., Suh, H.H., & Mittleman, M.A. 2009. Weather and air pollution as triggers of severe headaches. *Neurology*, 72, (10) 922-927 available from:

ISI:000264005000012

Ref ID: 1990

Pope, C.A., Renlund, D.G., Kfoury, A.G., May, H.T., & Horne, B.D. 2008. Relation of Heart Failure Hospitalization to Exposure to Fine Particulate Air Pollution. *American Journal of Cardiology*, 102, (9) 1230-1234 available from: ISI:000261007500023 Ref ID: 1997

Stoelzel, M., Breitner, S., Cyrys, J., Pitz, M., Woelke, G., Kreyling, W., Heinrich, J., Wichmann, H.E., & Peters, A. 2007. Daily mortality and particulate matter in different size classes in Erfurt, Germany. *Journal of Exposure Science and Environmental Epidemiology*, 17, (5) 458-467 available from: ISI:000248674400005

Ref ID: 2014

Blanchard, M., Borrelli, D., Chardon, B., Chatignoux, E., Declercq, C., Fabre, P., Host, S., Jusot, J. F., Larrieu, S., Lefranc, A., Medina, S., Pascal, L., Prouvost, H., Saoudi, A., & Wagner, V. Analysis of short-term links between urban air pollution and mortality in nine French cities; Analyse des liens a court terme entre pollution atmospherique urbaine et mortalite dans neuf villes francaises. 2008. Programme de surveillance air et sante.

Barnett, A.G., Williams, G.M., Schwartz, J., Neller, A.H., Best, T.L., Petroeschevsky, A.L., & Simpson, R.W. 2005. Air pollution and child respiratory health - A case-crossover study in Australia and new Zealand. *American Journal of Respiratory and Critical Care Medicine*, 171, (11) 1272-1278 available from: ISI:000229410800013

Ref ID: 2039

Branis, M., Vyskovska, J., Maly, M., & Hovorka, J. 2010. Association of size-resolved number concentrations of particulate matter with cardiovascular and respiratory hospital admissions and mortality in Prague, Czech Republic. *Inhalation Toxicology*, 22, Suppl-8 Ref ID: 2051

Haley, V.B., Talbot, T.O., & Felton, H.D. 2009. Surveillance of the short-term impact of fine particle air pollution on cardiovascular disease hospitalizations in New York State. *Environmental Health*, 8, available from: ISI:000270885600001 Ref ID: 2056

Ignotti, E., Hacon, S.D., Junger, W.L., Mourao, D., Longo, K., Freitas, S., Artaxo, P., & De Leon, A.C.M.P. 2010. Air pollution and hospital admissions for respiratory diseases in the subequatorial Amazon: a time series approach. *Cadernos de Saude Publica*, 26, (4) 747-761 available from: ISI:000278148700011 Ref ID: 2059

Linares, C. & Diaz, J. 2010. Short-term effect of PM2.5 on daily hospital admissions in Madrid (2003-2005). *International Journal of Environmental Health Research*, 20, (2) 129-140 available from: ISI:000275411200004

Ref ID: 2063

Lopez-Villarrubia, E., Ballester, F., Iniguez, C., & Peral, N. 2010. Air pollution and mortality in the Canary Islands: a time series analysis. *Environmental Health*, 9, available from: ISI:000275908600001

Ref ID: 2064

Mate, T., Guaita, R., Pichiule, M., Linares, C., & Diaz, J. 2010. Short-term effect of fine particulate matter (PM2.5) on daily mortality due to diseases of the circulatory system in Madrid (Spain). *Science of the Total Environment*, 408, (23) 5750-5757 available from: ISI:000285070700016 Ref ID: 2065

Silverman, R.A. & Ito, K. 2010. Age-related association of fine particles and ozone with severe acute asthma in New York City. *Journal of Allergy and Clinical Immunology*, 125, (2) 367-373 available from: ISI:000274764000013 Ref ID: 2071

Yorifuji, T., Kawachi, I., Sakamoto, T., & Doi, H. 2011. Associations of outdoor air pollution with hemorrhagic stroke mortality. *Journal of Occupational and Environmental Medicine*, 53, (2) 124-126 available from: ISI:000287133100003 Ref ID: 2077

Zanobetti, A., Franklin, M., Koutrakis, P., & Schwartz, J. 2009. Fine particulate air pollution and its components in association with cause-specific emergency admissions. *Environmental Health*, 8, available from: ISI:000273661100001

Ref ID: 2078

Perez, L., Medina-Ramon, M., Kunzli, N., Alastuey, A., Pey, J., Perez, N., Garcia, R., Tobias, A., Querol, X., & Sunyer, J. 2009. Size fractionate particulate matter, vehicle traffic, and case-specific daily mortality in Barcelona, Spain. *Environmental Science & Technology*, 43, (13) 4707-4714 available from: ISI:000267435500017 Ref ID: 2112

Burnett, R.T., Stieb, D., Brook, J.R., akmak, S., les, R., izenne, M., ncent, R., & nn, T. 2004. Associations between Short-Term Changes in Nitrogen Dioxide and Mortality in Canadian Cities. *Environmental Health*, 59, (5) 228-236 Ref ID: 2120

Table S3 Meta-analysis results for cause-specific mortality by WHO region and overall

WHO Region	Alla (SC/MC)	Selected <sup>b</sup> (SC/MC	RE (95% CI) <sup>c</sup>	I <sup>2</sup> (%) <sup>d</sup>
Ischaemic Heart Disease				
AMR A	1/2	1/1	1.27 (0.60, 1.94)	
EUR A	2/0	2/0	5.90 (3.88, 7.95)	90
WPR A	0/1	0/1	5.40 (0.20, 10.87)	
Summarye	-	2/2	3.36 (0.68, 6.10)	
Stroke				
AMR A	0/3	0/1	1.78 (0.96, 2.61)	50
EUR A	2/0	2/0	5.44 (1.52, 9.52)	30
WPR A	1/0	1/0	1.30 (0.20, 2.41)	
Summarye	-	2/1	1.85 (0.74, 2.97)	
COPD (excl. Asthma)				
AMR A	2/1	1/1	1.81 (-0.57, 4.23)	72
EUR A	1/0	1/0	9.00 (5.11, 13.03)	12
Summarye	-	2/1	2.86 (-0.12, 5.93)	

Notes: a - Numbers of single-city(SC)/multi-city (MC) estimates available from all studies and b-Numbers of single-city(SC)/multi-city (MC) estimates selected for meta-analysis (see estimate selection protocol in Methods section); c - Random effects summary estimate (95% confidence interval) per  $10~\mu g/m^3$ ; d - $I^2$  statistic for heterogeneity; e - Estimate numbers for 'Summary' refers to the number of pooled (from single-city estimates) and multi-city estimates used to calculate the overall summary estimate across WHO Region

Table S4 Meta-analysis results for ages 65+ yrs. for cardiovascular admissions by WHO region and overall

	Alla	Selectedb		<u>I</u> 2
WHO Region	(SC/MC)	(SC/MC	RE (95% CI) <sup>c</sup>	(%) <sup>d</sup>
	(SG/MG)	(36) MC		(70)
Cardiovascular				
AMR A	0/3	0/1	0.71 (0.45, 0.97)	
EUR A	2/1	2/1	1.91 (0.92, 2.91)	85
WPR A	2/1	0/1	3.46 (1.59, 5.36)	
Summarye	, -	1/3	1.78 (0.48, 3.10)	
·		,		
Cardiac				
AMR A	1/1	0/1	1.89 (1.34, 2.44)	72
EUR A	1/1	1/1	3.69 (0.31, 7.19)	72
WPR A	1/1	0/1	5.08 (2.65, 7.56)	
Summary <sup>e</sup>	-	1/3	3.05 (1.64, 4.48)	
Ischaemic Heart Disease				
AMR A	3/2	1/1	0.47 (0.06, 0.89)	
EUR A	3/1	3/1	2.79 (-0.38, 6.07)	86
WPR A	1/1	0/1	7.26 (3.46, 11.21)	
Summary <sup>e</sup>	-	2/3	2.52 (0.53, 4.55)	
Stroke				
AMR A	2/1	1/1	0.81 (0.31, 1.31)	
EUR A	2/0	2/0	-1.58 (-3.59, 0.47)	79
WPR A	1/0	1/0	-3.06 (-6.31, 0.31)	
Summarye	-	3/1	-0.45 (-2.21, 1.33)	
и . п. а				
Heart Failure	2 /2	2 /1	270 ( 0 22 5 00)	<b>6 5</b>
AMR A	3/2	2/1	2.78 (-0.33, 5.98)	65
EUR A	1/0	1/0	3.58 (0.16, 7.11)	
WPR A	0/1	0/1	9.75 (4.81, 14.93)	
Summarye	-	2/2	4.39 (1.35, 7.53)	
Dysrhythmias				
AMR A	1/1	0/1	0.57 (-0.01, 1.15)	
EUR A	1/1	1/0	1.33 (-1.66, 4.40)	0
Summary <sup>e</sup>	-	1/0	0.60 (0.03, 1.17)	U
Summal y*	<u> </u>	1/1	0.00 (0.03, 1.17)	

Notes: a - Numbers of single-city(SC)/multi-city (MC) estimates available from all studies and b-Numbers of single-city(SC)/multi-city (MC) estimates selected for meta-analysis (see estimate selection protocol in Methods section); c - Random effects summary estimate (95% confidence interval) per  $10~\mu g/m^3$ ; d - $I^2$  statistic for heterogeneity; e - Estimate numbers for 'Summary' refers to the number of pooled (from single-city estimates) and multi-city estimates used to calculate the overall summary estimate across WHO Region

Table S5 Meta-analysis results for ages 65+ years & 0-14 years for respiratory admissions by WHO region and overall

Respiratory, 65+ years  AMR A 2/4 1/1 0.90 (0.39, 1.1)  EUR A 4/1 4/1 0.99 (-0.90, 2.92) 80  WPR A 1/0 1/0 1.23 (-1.30, 3.82)  Summary* - 3/2 0.91 (0.43, 1.40)  COPD (incl. asthma), 65+ years  AMR A 1/1 1/1 7.48 (-6.91, 24.10)  EUR A 2/0 2/0 -0.49 (-3.80, 2.93)  Summary* - 2/1 1.85 (-2.07, 5.93)  COPD (excl. asthma), 65+ years  AMR A 3/0 2/0 1.90 (0.37, 3.46)  EUR A 2/0 2/0 3.93 (1.06, 6.89)  Summary* - 2/0 2.36 (1.0, 3.73)  Lower Respiratory Infection, 65+ years  AMR A 3/0 2/0 3.88 (1.62, 6.20)  EUR A 2/0 2/0 4.05 (0.97, 7.22) 0  Summary* - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36)  AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76  EUR A 2/1 2/1 0.32 (-1.18, 1.84)  WPR A 0/1 0/1 6.44 (2.65, 10.37)  Summary* - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28)  EUR A 2/0 2/0 12.27 (-10.64, 41.06)  WPR A 1/1 1/1 5.08 (2.28, 7.95) 33	WHO Region	Alla (SC/MC)	Selected <sup>b</sup> (SC/MC	RE (95% CI) <sup>c</sup>	I <sup>2</sup> (%) <sup>d</sup>		
AMR A 2/4 1/1 0.90 (0.39, 1.1) EUR A 4/1 4/1 0.99 (-0.90, 2.92) 80 WPR A 1/0 1/0 1.23 (-1.30, 3.82) Summarye - 3/2 0.91 (0.43, 1.40)  COPD (incl. asthma), 65+ years  AMR A 1/1 1/1 7.48 (-6.91, 24.10) EUR A 2/0 2/0 -0.49 (-3.80, 2.93) Summarye - 2/1 1.85 (-2.07, 5.93)  COPD (excl. asthma), 65+ years  AMR A 3/0 2/0 1.90 (0.37, 3.46) EUR A 2/0 2/0 3.93 (1.06, 6.89) Summarye - 2/0 3.93 (1.06, 6.89) Summarye - 2/0 3.93 (1.06, 6.89) Summarye - 2/0 3.93 (1.06, 6.89) EUR A 2/0 2/0 4.05 (0.97, 7.22) 0 Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76 EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)	Respiratory 65+ years						
EUR A 4/1 4/1 0.99 (-0.90, 2.92) 80  WPR A 1/0 1/0 1.23 (-1.30, 3.82)  Summarye - 3/2 0.91 (0.43, 1.40)  COPD (incl. asthma), 65+ years  AMR A 1/1 1/1 7.48 (-6.91, 24.10)  EUR A 2/0 2/0 -0.49 (-3.80, 2.93)  Summarye - 2/1 1.85 (-2.07, 5.93)  COPD (excl. asthma), 65+ years  AMR A 3/0 2/0 1.90 (0.37, 3.46)  EUR A 2/0 2/0 3.93 (1.06, 6.89)  Summarye - 2/0 3.93 (1.06, 6.89)  Summarye - 2/0 3.93 (1.06, 6.89)  Summarye - 2/0 3.88 (1.62, 6.20)  EUR A 2/0 2/0 4.05 (0.97, 7.22)  Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36)  AMR B 2/0 2/0 10.84 (-2.54, 26.05)  EUR A 2/1 2/1 0.32 (-1.18, 1.84)  WPR A 0/1 0/1 6.44 (2.65, 10.37)  Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28)  EUR A 2/0 2/0 12.27 (-10.64, 41.06)	1 0. 0	2/4	1 /1	0.90 (0.39.1.1)			
WPR A 1/0 1/0 1.23 (-1.30, 3.82) Summarye - 3/2 0.91 (0.43, 1.40)  COPD (incl. asthma), 65+ years  AMR A 1/1 1/1 7.48 (-6.91, 24.10) EUR A 2/0 2/0 -0.49 (-3.80, 2.93) Summarye - 2/1 1.85 (-2.07, 5.93)  COPD (excl. asthma), 65+ years  AMR A 3/0 2/0 1.90 (0.37, 3.46) EUR A 2/0 2/0 3.93 (1.06, 6.89) Summarye - 2/0 2.36 (1.0, 3.73)  Lower Respiratory Infection, 65+ years  AMR A 3/0 2/0 3.88 (1.62, 6.20) EUR A 2/0 2/0 4.05 (0.97, 7.22) 0 Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76 EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)		· ·	=		80		
Summarye - 3/2 0.91 (0.43, 1.40)  COPD (incl. asthma), 65+ years  AMR A 1/1 1/1 7.48 (-6.91, 24.10) EUR A 2/0 2/0 -0.49 (-3.80, 2.93) Summarye - 2/1 1.85 (-2.07, 5.93)  COPD (excl. asthma), 65+ years  AMR A 3/0 2/0 1.90 (0.37, 3.46) EUR A 2/0 2/0 3.93 (1.06, 6.89) Summarye - 2/0 2.36 (1.0, 3.73)  Lower Respiratory Infection, 65+ years  AMR A 3/0 2/0 3.88 (1.62, 6.20) EUR A 2/0 2/0 4.05 (0.97, 7.22) 0 Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76 EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)		•	-	-	00		
AMR A 1/1		-		•			
AMR A 1/1	COPD (incl. aethma) 65+ years						
EUR A 2/0 2/0 -0.49 (-3.80, 2.93) Summarye - 2/1 1.85 (-2.07, 5.93)  COPD (excl. asthma), 65+ years  AMR A 3/0 2/0 1.90 (0.37, 3.46) EUR A 2/0 2/0 3.93 (1.06, 6.89) Summarye - 2/0 2.36 (1.0, 3.73)  Lower Respiratory Infection, 65+ years  AMR A 3/0 2/0 3.88 (1.62, 6.20) EUR A 2/0 2/0 4.05 (0.97, 7.22) 0 Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76 EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)	` .		1 /1	7 48 (-6 91 24 10)			
Summarye - 2/1 1.85 (-2.07, 5.93)  COPD (excl. asthma), 65+ years  AMR A 3/0 2/0 1.90 (0.37, 3.46) EUR A 2/0 2/0 3.93 (1.06, 6.89) Summarye - 2/0 2.36 (1.0, 3.73)  Lower Respiratory Infection, 65+ years  AMR A 3/0 2/0 3.88 (1.62, 6.20) EUR A 2/0 2/0 4.05 (0.97, 7.22) 0 Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76 EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)		•			4		
AMR A 3/0 2/0 1.90 (0.37, 3.46) 32  EUR A 2/0 2/0 3.93 (1.06, 6.89)  Summarye - 2/0 2.36 (1.0, 3.73)  Lower Respiratory Infection, 65+ years  AMR A 3/0 2/0 3.88 (1.62, 6.20)  EUR A 2/0 2/0 4.05 (0.97, 7.22) 0  Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36)  AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76  EUR A 2/1 2/1 0.32 (-1.18, 1.84)  WPR A 0/1 0/1 6.44 (2.65, 10.37)  Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28)  EUR A 2/0 2/0 12.27 (-10.64, 41.06)		-		•			
AMR A 3/0 2/0 1.90 (0.37, 3.46) 32  EUR A 2/0 2/0 3.93 (1.06, 6.89) 32  Summarye - 2/0 2.36 (1.0, 3.73)  Lower Respiratory Infection, 65+ years  AMR A 3/0 2/0 3.88 (1.62, 6.20) EUR A 2/0 2/0 4.05 (0.97, 7.22) 0  Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76  EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)	CODD (ovel authma) 65 Ly	oara					
EUR A 2/0 2/0 3.93 (1.06, 6.89) Summarye - 2/0 2.36 (1.0, 3.73)  Lower Respiratory Infection, 65+ years  AMR A 3/0 2/0 3.88 (1.62, 6.20) EUR A 2/0 2/0 4.05 (0.97, 7.22) 0 Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76 EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)			2 /0	1 00 (0 27 2 46)			
Summarye - 2/0 2.36 (1.0, 3.73)  Lower Respiratory Infection, 65+ years  AMR A 3/0 2/0 3.88 (1.62, 6.20)  EUR A 2/0 2/0 4.05 (0.97, 7.22) 0  Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36)  AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76  EUR A 2/1 2/1 0.32 (-1.18, 1.84)  WPR A 0/1 0/1 6.44 (2.65, 10.37)  Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28)  EUR A 2/0 2/0 12.27 (-10.64, 41.06)		•	•	•	32		
AMR A 3/0 2/0 3.88 (1.62, 6.20) EUR A 2/0 2/0 4.05 (0.97, 7.22) 0 Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76 EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)		2/U -		•			
AMR A 3/0 2/0 3.88 (1.62, 6.20) EUR A 2/0 2/0 4.05 (0.97, 7.22) 0 Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76 EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)							
EUR A 2/0 2/0 4.05 (0.97, 7.22) 0 Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76  EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)		=	2.40	2.00 (4.62.6.20)			
Summarye - 2/0 3.94 (2.11, 5.80)  Respiratory, 0-14 years  AMR A 0/1 0/1 2.74 (1.14, 4.36)  AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76  EUR A 2/1 2/1 0.32 (-1.18, 1.84)  WPR A 0/1 0/1 6.44 (2.65, 10.37)  Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28)  EUR A 2/0 2/0 12.27 (-10.64, 41.06)		•	•	•	0		
Respiratory, 0-14 years  AMR A  O/1  O/1  O/1  2.74 (1.14, 4.36)  AMR B  2/0  2/0  10.84 (-2.54, 26.05)  76  EUR A  2/1  O/1  O/1  6.44 (2.65, 10.37)  Summarye  -  2/3  2.45 (0.12, 4.85)  ASthma, 0-14 years  AMR A  4/1  3/1  -1.67 (-9.88, 7.28)  EUR A  2/0  2/0  12.27 (-10.64, 41.06)		2/0	-	•	Ü		
AMR A 0/1 0/1 2.74 (1.14, 4.36) AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76 EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)	Summarye	-	2/0	3.94 (2.11, 5.80)			
AMR B 2/0 2/0 10.84 (-2.54, 26.05) 76  EUR A 2/1 2/1 0.32 (-1.18, 1.84)  WPR A 0/1 0/1 6.44 (2.65, 10.37)  Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28)  EUR A 2/0 2/0 12.27 (-10.64, 41.06)	Respiratory, 0-14 years						
EUR A 2/1 2/1 0.32 (-1.18, 1.84) WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)	AMR A	0/1	0/1	2.74 (1.14, 4.36)			
WPR A 0/1 0/1 6.44 (2.65, 10.37) Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)	AMR B	2/0	2/0	10.84 (-2.54, 26.05)	76		
Summarye - 2/3 2.45 (0.12, 4.85)  Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28)  EUR A 2/0 2/0 12.27 (-10.64, 41.06)	EUR A	2/1	2/1	0.32 (-1.18, 1.84)			
Asthma, 0-14 years  AMR A 4/1 3/1 -1.67 (-9.88, 7.28)  EUR A 2/0 2/0 12.27 (-10.64, 41.06)	WPR A	0/1	0/1	6.44 (2.65, 10.37)			
AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)	Summary <sup>e</sup>	-	2/3	2.45 (0.12, 4.85)			
AMR A 4/1 3/1 -1.67 (-9.88, 7.28) EUR A 2/0 2/0 12.27 (-10.64, 41.06)	Asthma, 0-14 years						
EUR A 2/0 2/0 12.27 (-10.64, 41.06)	<u>-</u>	4/1	3/1	-1.67 (-9.88, 7.28)			
			=	=			
		•	=		33		
WPR B 2/0 1/0 2.40 (1.30, 3.51)	WPR B	=		•			
Summary <sup>e</sup> - 4/2 <sup>c</sup> 2.29 (-0.09, 4.73)		-	-				

Notes: a - Numbers of single-city(SC)/multi-city (MC) estimates available from all studies and b-Numbers of single-city(SC)/multi-city (MC) estimates selected for meta-analysis (see estimate selection protocol in Methods section); c - Random effects summary estimate (95% confidence interval) per  $10~\mu g/m^3$ ; d  $-I^2$  statistic for heterogeneity; e - Estimate numbers for 'Summary' refers to the number of pooled (from single-city estimates) and multi-city estimates used to calculate the overall summary estimate across WHO Region

Figure S1




Figure S2




Figure S3




Figure S4




Figure S5




Figure S6




Figure S7




Figure S8




Figure S9




Figure S10




Figure S11




Figure S12




Figure S13




Figure S14




Figure S15




Figure S16




Figure S17




Figure S18




Figure S19




Figure S20

